Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Metamia, Ciampricotti"'
Autor:
Alvaro Quintanal-Villalonga, Kenta Kawasaki, Esther Redin, Fathema Uddin, Swanand Rakhade, Vidushi Durani, Amin Sabet, Moniquetta Shafer, Wouter R. Karthaus, Samir Zaidi, Yingqian A. Zhan, Parvathy Manoj, Harsha Sridhar, Dennis Kinyua, Hong Zhong, Barbara P. Mello, Metamia Ciampricotti, Umesh K. Bhanot, Irina Linkov, Juan Qiu, Radhika A. Patel, Colm Morrissey, Sanjoy Mehta, Jesse Barnes, Michael C. Haffner, Nicholas D. Socci, Richard P. Koche, Elisa de Stanchina, Sonia Molina-Pinelo, Sohrab Salehi, Helena A. Yu, Joseph M. Chan, Charles M. Rudin
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-14 (2024)
Abstract Neuroendocrine (NE) transformation is a mechanism of resistance to targeted therapy in lung and prostate adenocarcinomas leading to poor prognosis. Up to date, even if patients at high risk of transformation can be identified by the occurren
Externí odkaz:
https://doaj.org/article/501fe4c8a5e9423ca573e0d9f455d0b2
Autor:
Anastasia-Maria Zavitsanou, Ray Pillai, Yuan Hao, Warren L. Wu, Eric Bartnicki, Triantafyllia Karakousi, Sahith Rajalingam, Alberto Herrera, Angeliki Karatza, Ali Rashidfarrokhi, Sabrina Solis, Metamia Ciampricotti, Anna H. Yeaton, Ellie Ivanova, Corrin A. Wohlhieter, Terkild B. Buus, Makiko Hayashi, Burcu Karadal-Ferrena, Harvey I. Pass, John T. Poirier, Charles M. Rudin, Kwok-Kin Wong, Andre L. Moreira, Kamal M. Khanna, Aristotelis Tsirigos, Thales Papagiannakopoulos, Sergei B. Koralov
Publikováno v:
Cell Reports, Vol 42, Iss 11, Pp 113295- (2023)
Summary: Lung cancer treatment has benefited greatly through advancements in immunotherapies. However, immunotherapy often fails in patients with specific mutations like KEAP1, which are frequently found in lung adenocarcinoma. We established an anti
Externí odkaz:
https://doaj.org/article/240bdf74cb4547dea3fb1640afd7bcf5
Autor:
Janneke E. Jaspers, Jonathan F. Khan, William D. Godfrey, Andrea V. Lopez, Metamia Ciampricotti, Charles M. Rudin, Renier J. Brentjens
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 9 (2023)
Patients with small cell lung cancer (SCLC) generally have a poor prognosis and a median overall survival of only about 13 months, indicating the urgent need for novel therapies. Delta-like protein 3 (DLL3) has been identified as a tumor-specific cel
Externí odkaz:
https://doaj.org/article/1add364070234a5a9f42731c9c6e16d1
Autor:
Alvaro Quintanal-Villalonga, Hirokazu Taniguchi, Yingqian A. Zhan, Maysun M. Hasan, Shweta S. Chavan, Fanli Meng, Fathema Uddin, Viola Allaj, Parvathy Manoj, Nisargbhai S. Shah, Joseph M. Chan, Metamia Ciampricotti, Andrew Chow, Michael Offin, Jordana Ray-Kirton, Jacklynn D. Egger, Umesh K. Bhanot, Irina Linkov, Marina Asher, Michael H. Roehrl, Katia Ventura, Juan Qiu, Elisa de Stanchina, Jason C. Chang, Natasha Rekhtman, Brian Houck-Loomis, Richard P. Koche, Helena A. Yu, Triparna Sen, Charles M. Rudin
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-19 (2021)
Abstract Background Lineage plasticity, the ability to transdifferentiate among distinct phenotypic identities, facilitates therapeutic resistance in cancer. In lung adenocarcinomas (LUADs), this phenomenon includes small cell and squamous cell (LUSC
Externí odkaz:
https://doaj.org/article/4c6ed1ab46b04936a848bae9af7bc67d
Autor:
Rebecca Caeser, Christopher Hulton, Emily Costa, Vidushi Durani, Megan Little, Xiaoping Chen, Sam E. Tischfield, Marina Asher, Faruk Erdem Kombak, Shweta S. Chavan, Nisargbhai S. Shah, Metamia Ciampricotti, Elisa de Stanchina, John T. Poirier, Charles M. Rudin, Triparna Sen
Publikováno v:
iScience, Vol 24, Iss 11, Pp 103224- (2021)
Summary: Activation of mitogenic signaling pathways is a common oncogenic driver of many solid tumors including lung cancer. Although activating mutations in the mitogen-activated protein kinase (MAPK) pathway are prevalent in non-small cell lung can
Externí odkaz:
https://doaj.org/article/408084487e324b9abf64eba52e8ffc2a
Autor:
Charles M. Rudin, Thales Papagiannakopoulos, John T. Poirier, Trudy G. Oliver, Triparna Sen, Mark T.A. Donoghue, Tyler Jacks, Elliot H. Akama-Garren, William M. Rideout, Andrea Ventura, Danilo Maddalo, Anastasia-Maria Zavitsanou, Janneke E. Jaspers, Francisco J. Sanchez-Rivera, Faruk E. Kombak, Kyle B. Spainhower, Parvathy Manoj, Viola Allaj, Emily A. Costa, Rebecca Caeser, Angeliki Karatza, Àlvaro Quintanal-Villalonga, Allison L. Richards, Triantafyllia Karakousi, Metamia Ciampricotti
Supplementary Figures S1 - S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85e21dac3fbf8c8abfbd8d681c0ce639
https://doi.org/10.1158/2159-8290.22540609
https://doi.org/10.1158/2159-8290.22540609
Autor:
Triparna Sen, Charles M. Rudin, Richard P. Koche, Brian Loomis, John T. Poirier, Natasha Rekhtman, Marina K. Baine, Elisa de Stanchina, Juan Qiu, Helena A. Yu, Travis J. Hollmann, Michael H. Roehrl, Christine A. Iacobuzio-Donahue, Joachim Silber, Sonali Sinha, Marina Asher, Irina Linkov, Umesh K. Bhanot, Jacklynn Egger, Sam E. Tischfield, Jordana Ray-Kirton, Jason C. Chang, Michael Offin, Andrew Chow, Metamia Ciampricotti, Joseph M. Chan, Helen H. Won, Mark T.A. Donoghue, Parvathy Manoj, Fathema Uddin, Fanli Meng, Shweta S. Chavan, Maysun M. Hasan, Yingqian A. Zhan, Hirokazu Taniguchi, Alvaro Quintanal-Villalonga
Lineage plasticity is implicated in treatment resistance in multiple cancers. In lung adenocarcinomas (LUAD) amenable to targeted therapy, transformation to small cell lung cancer (SCLC) is a recognized resistance mechanism. Defining molecular mechan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19866bcbfca6f0bd1b206c8dae81ff58
https://doi.org/10.1158/2159-8290.c.6549461
https://doi.org/10.1158/2159-8290.c.6549461
Autor:
Triparna Sen, Charles M. Rudin, Richard P. Koche, Brian Loomis, John T. Poirier, Natasha Rekhtman, Marina K. Baine, Elisa de Stanchina, Juan Qiu, Helena A. Yu, Travis J. Hollmann, Michael H. Roehrl, Christine A. Iacobuzio-Donahue, Joachim Silber, Sonali Sinha, Marina Asher, Irina Linkov, Umesh K. Bhanot, Jacklynn Egger, Sam E. Tischfield, Jordana Ray-Kirton, Jason C. Chang, Michael Offin, Andrew Chow, Metamia Ciampricotti, Joseph M. Chan, Helen H. Won, Mark T.A. Donoghue, Parvathy Manoj, Fathema Uddin, Fanli Meng, Shweta S. Chavan, Maysun M. Hasan, Yingqian A. Zhan, Hirokazu Taniguchi, Alvaro Quintanal-Villalonga
Supplemental figures and figure legends.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15cdf6100787567edd1d3c55a0d31bc8
https://doi.org/10.1158/2159-8290.22540724
https://doi.org/10.1158/2159-8290.22540724
Autor:
Triparna Sen, Charles M. Rudin, Richard P. Koche, Brian Loomis, John T. Poirier, Natasha Rekhtman, Marina K. Baine, Elisa de Stanchina, Juan Qiu, Helena A. Yu, Travis J. Hollmann, Michael H. Roehrl, Christine A. Iacobuzio-Donahue, Joachim Silber, Sonali Sinha, Marina Asher, Irina Linkov, Umesh K. Bhanot, Jacklynn Egger, Sam E. Tischfield, Jordana Ray-Kirton, Jason C. Chang, Michael Offin, Andrew Chow, Metamia Ciampricotti, Joseph M. Chan, Helen H. Won, Mark T.A. Donoghue, Parvathy Manoj, Fathema Uddin, Fanli Meng, Shweta S. Chavan, Maysun M. Hasan, Yingqian A. Zhan, Hirokazu Taniguchi, Alvaro Quintanal-Villalonga
Supplemental tables S1-S15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b59aeae9efc033bbf7f750d12903ac3
https://doi.org/10.1158/2159-8290.22540718
https://doi.org/10.1158/2159-8290.22540718
Autor:
Charles M. Rudin, Thales Papagiannakopoulos, John T. Poirier, Trudy G. Oliver, Triparna Sen, Mark T.A. Donoghue, Tyler Jacks, Elliot H. Akama-Garren, William M. Rideout, Andrea Ventura, Danilo Maddalo, Anastasia-Maria Zavitsanou, Janneke E. Jaspers, Francisco J. Sanchez-Rivera, Faruk E. Kombak, Kyle B. Spainhower, Parvathy Manoj, Viola Allaj, Emily A. Costa, Rebecca Caeser, Angeliki Karatza, Àlvaro Quintanal-Villalonga, Allison L. Richards, Triantafyllia Karakousi, Metamia Ciampricotti
Small cell lung cancer (SCLC) has limited therapeutic options and an exceptionally poor prognosis. Understanding the oncogenic drivers of SCLC may help define novel therapeutic targets. Recurrent genomic rearrangements have been identified in SCLC, m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e119dfd0f00e496d01bd3fbdec93d54
https://doi.org/10.1158/2159-8290.c.6549427.v1
https://doi.org/10.1158/2159-8290.c.6549427.v1